期刊文献+

蒙古国人丙型肝炎患者HCV RNA检测及基因型的研究 被引量:1

Detection and Genotyping of HCV RNA in Patients with Positive Anti-HCV Sera in Mongolia
原文传递
导出
摘要 目的通过检测丙型肝炎病毒基因分型,探讨蒙古国抗-HCV阳性患者血清中HCV基因型流行株特征。方法采用基因芯片法对蒙古国183例抗-HCV阳性患者血清标本进行基因型检测,同时检测相关病毒学及肝功能生化指标,分析基因型分布特点和临床意义。结果 183例抗-HCV阳性患者中HCV RNA阳性134例(73.2%),其中基因1b型68例(50.7%),2a型59例(44.0%),并有少量的1a、3a、1b+2a和其它3例混合型。结论抗-HCV阳性并非HCV感染直接标志,蒙古国感染HCV患者的基因型以1b和2a型为主,比例基本相当;基因型在性别上人群分布差异无统计学意义。 Objective To investigate the characteristics of the predominant epidemic genotype of the hepatitis C virus(HCV) in the patients with positive anti-HCV sera in Mongolia by HCV genotyping.Methods The genotype of HCV was identified by the gene-chip method in 183 Mongolian patients with positive anti-HCV sera and the virological and biochemical markers were detected.The characteristics of the genotype distribution and its clinical significance were analyzed.Results Totally,134 out of 183 anti-HCV positive sera(73.2%) were HCV RNA positive,including 68 cases(50.7%) of 1b genotype,59 cases(44.0%) of 2a genotype,a few cases of 1a,3a or 1b+2a genotype,and 3 cases of mixed genotype.Conclusions Presence of anti-HCV is not the direct marker of hepatitis C infection.For the patients with positive anti-HCV sera in Mongolia,the major HCV genotypes are 1b and 2a,with almost equal ratios.The distribution of the genotypes does not differ between genders.
出处 《实用预防医学》 CAS 2012年第12期1867-1869,共3页 Practical Preventive Medicine
关键词 丙型肝炎病毒 基因型 蒙古国 Hepatitis C virus Genotype Mongolia
  • 相关文献

参考文献5

二级参考文献37

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:732
  • 2谷金莲,祁自柏,王尊文,张华远,于洋,扬振.丙型肝炎病毒抗体试剂检测结果的可信度分析[J].中华检验医学杂志,2005,28(6):580-583. 被引量:59
  • 3尹建平,张红,马威,王曦.丙型肝炎病毒感染的危险因素病例对照研究[J].数理医药学杂志,2005,18(5):455-457. 被引量:11
  • 4杨东亮,郝连杰.我国丙型肝炎病毒基因变异及分型研究现状[J].中华传染病杂志,1996,14(1):41-44. 被引量:25
  • 5Simmonds P,Mcomish F,Yap PL,et al.Sequence variability in the 5'-non-coding region of hepatitis C virus:identification of a new vims type and restrictions on sequence diversity.J Gen Virol,1993,74:661-668.
  • 6Liew M,Erali M,Page S,et al.Hepatitis C genotyping by denaturing high-performance liquid chromatography.Clin Microbiol,2004,42(1):158.
  • 7Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 8Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 9Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 10Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.

共引文献834

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部